SCHEMBL7032175

SCHEMBL7032175

CCCNC(=O)/C=C\C(N)=O.C[SiH](C)O[SiH3]

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.36
LMNA P02545 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAPT P10636 3/20 0.36
HTT P42858 2/20 0.36
PKM P14618 1/20 0.36
NLRP1 Q9C000 1/20 0.36
ZDHHC20 Q5W0Z9 3/20 0.35
ZDHHC2 Q9UIJ5 3/20 0.35
MCL1 Q07820 1/20 0.35
PELI1 Q96FA3 2/20 0.34
RAB9A P51151 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
DDAH1 O94760 1/20 0.32
GAA P10253 1/20 0.31
CNR1 P21554 2/20 0.31
CNR2 P34972 2/20 0.31
MMP1 P03956 1/20 0.31
MMP2 P08253 1/20 0.31
MMP3 P08254 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL380975 0.86 ALDH1A1 (0.44) ALDH1A1LMNASMN1; SMN2MAPTHTT
SCHEMBL380976 0.86 ALDH1A1 (0.44) ALDH1A1LMNASMN1; SMN2MAPTHTT
Ammonia Solution, Strong SCHEMBL2389741 0.84 ALDH1A1 (0.42) ALDH1A1LMNASMN1; SMN2MAPTHTT
Ammonia Solution, Strong SCHEMBL2389744 0.84 ALDH1A1 (0.42) ALDH1A1LMNASMN1; SMN2MAPTHTT
SCHEMBL1700849 0.76 ALDH1A1 (0.50) ALDH1A1LMNASMN1; SMN2MAPTHTT
SCHEMBL2536904 0.76 ALDH1A1 (0.50) ALDH1A1LMNASMN1; SMN2MAPTHTT
SCHEMBL3419359 0.76 MMP1 (0.30) MMP1MMP2MMP3MMP9
SCHEMBL3105960 0.75 ZDHHC20 (0.48) ALDH1A1MAPTHTTZDHHC20ZDHHC2
SCHEMBL380522 0.75 ZDHHC20 (0.48) ALDH1A1MAPTHTTZDHHC20ZDHHC2
SCHEMBL380523 0.75 ZDHHC20 (0.48) ALDH1A1MAPTHTTZDHHC20ZDHHC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors HARTER WILLIAM GLEN (US) 2003-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors MMP13, MMP3, MMP25 ALDH1A1 812/4885LMNA 1210/4885SMN1; SMN2 2160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.